The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Galantamine for Alzheimer's disease and mild cognitive impairment
Open accessAbstract
BACKGROUND: Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. OBJECTIVES: To assess the clinical effects of galantamine in patients with mild cognitive impairment (MCI), probable or possible Alzheimer's disease (AD), and potential moderators of effect. SEARCH STRATEGY: The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, last updated on 25 April 2005 using the terms galanthamin*, galantamin* and Reminyl. Published reviews were inspected for further sources. Additional information was collected from unpublished clinical research reports for galantamine obtained from Janssen and from http://www.clinicalstudyresults.org/. SELECTION CRITERIA: Trials selected were randomised, double-blind, parallel-group comparisons of galantamine with placebo for a treatment duration of greater than 4 weeks in subjects with MCI or AD. DATA COLLECTION AND ANALYSIS: Data were extracted independently by the reviewers and pooled where appropriate and possible. Outcomes of interest include the clinical global impression of change (CIBIC-plus or CGIC), Alzheimer's Disease Assessment Scale-cognitive sub scale (ADAS-cog), Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL), Disability Assessment for Dementia scale (DAD) and Neuropsychiatric Inventory (NPI). Potential moderating variables of treatment effect assessed included trial duration, dose, and diagnosis of possible versus probable Alzheimer's disease. MAIN RESULTS: Ten trials with a total 6805 subjects were included in the analysis. Treatment with galantamine led to a significantly greater proportion of subjects with improved or unchanged global rating scale rating (k = 8 studies), at all dosing levels except for 8 mg/d . Confidence intervals for the ORs overlapped across the dose range of 16 mg to 36 mg per day, with point estimates of 1.6 - 1.8 when analysed with the intention-to-treat sample. Treatment with galantamine also led to significantly greater reduction in ADAS-cog score at all dosing levels (k = 8), with greater effect over six months compared to three months. Confidence intervals again overlapped. Point estimate of effect was lower for 8 mg/d but similar for 16 mg to 36 mg per day. For example, treatment effect for 24 mg/d over six months was 3.1 point reduction in ADAS-cog (95%CI 2.6-3.7, k = 4, ITT).ADCS-ADL, DAD and NPI were reported only in a small proportion of trials: all showed significant treatment effect in some individual trials at least. Confidence interval of treatment effect for the one trial recruiting patients with possible AD overlapped with the other seven recruiting patients with probable AD. Galantamine's adverse effects appeared similar to those of other cholinesterase inhibitors and to be dose related. Prolong release / once daily formulation of galantamine at 16 - 24mg/d was found to have similar efficacy and side-effect profile as the equivalent twice-daily regime. Data from the two MCI trials suggest marginal clinical benefit, but a yet unexplained excess in death rate. AUTHORS' CONCLUSIONS: Subjects in these trials were similar to those seen in earlier anti dementia AD trials, consisting primarily of mildly to moderately impaired outpatients. Galantamine's effect on more severely impaired subjects has not yet been assessed.Nevertheless, this review shows consistent positive effects for galantamine for trials of three to six months' duration. Although there was not a statistically significant dose-response effect, doses above 8 mg/d were, for the most part, consistently statistically significant. Galantamine's safety profile in AD is similar to that of other cholinesterase inhibitors with respect to cholinergically mediated gastrointestinal symptoms. It appears that doses of 16 mg/d were best tolerated in the single trial where medication was titrated over a four week period, and because this dose showed statistically indistinguishable efficacy with higher doses, it is probably most preferable initially. Longer term use of galantamine has not been assessed in a controlled fashion. Galantamine use in MCI is not recommended due to its association with an excess death rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,526
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Galasko, D. R., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. H. (1997) · PubMed · Cited by 767
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Self-citationWilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 626
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Nordberg, A., & Svensson, A.-L. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Treatment of early Parkinson's disease
Marsh, L., & Dawson, T. M. (2000) · BMJ · doi:10.1136/bmj.321.7252.1 · Cited by 337
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood, K. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.5.589 · Cited by 279
Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., & Waugh, N. (2001) · Health Technology Assessment · doi:10.3310/hta5010 · Cited by 246
Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease
Wilkinson, D., Murray, J., & the Galantamine Research Group (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.409 · Cited by 212
Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
Thomsen, T., & Kewitz, H. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90429-u · Cited by 207
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00004 · Cited by 202
Alzheimer's Disease: Biology, Diagnosis and Therapeutics
Hier, D. B. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00025 · Cited by 198
Cummings, J. L., Schneider, L., Tariot, P. N., Kershaw, P. R., & Yuan, W. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.532 · Cited by 183
Self-citationThe pharmacology of galanthamine and its analogues
Harvey, A. L. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)02002-0 · Cited by 169
MacGowan, S. H., Wilcock, G. K., & Scott, M. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199809)13:9<625::aid-gps835>3.0.co;2-2 · Cited by 139
Galantamine hydrobromide: An agent for Alzheimer’s disease
Zarotsky, V., Sramek, J. J., & Cutler, N. R. (2003) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/60.5.446 · Cited by 134
Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease
Brodaty, H., Corey‐Bloom, J., Potocnik, F. C. V., Truyen, L., Gold, M., & Damaraju, C. V. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000086613 · Cited by 122
Jones, R. W., Soininen, H. S., Häger, K., Aarsland, D., Passmore, P., Murthy, A. K., Zhang, R., & Bahra, R. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1038 · Cited by 118
Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition
Bickel, U., Thomsen, T., Weber, W., Fischer, J. P., Bachus, R., Nitz, M., & Kewitz, H. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.159 · Cited by 94
(1957) · International Organization · doi:10.1017/s0020818300024115 · Cited by 91
A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
Sweeney, J. E., Höhmann, C. F., Moran, T. H., & COYLE, J. T. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90325-5 · Cited by 85
Assessment of health economics in Alzheimer’s disease (AHEAD): Galantamine treatment in Canada
Getsios, D., Caro, J. J., Caro, G., Ishak, K., & for the AHEAD Study Group (2001) · Neurology · doi:10.1212/wnl.57.6.972 · Cited by 80
Erkinjuntti, T., Kurz, A., Small, G. W., Bullock, R. A., Lilienfeld, S., & Damaraju, C. V. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80168-6 · Cited by 79
Pacheco, G., Palacios, R., & Moss, D. E. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10622-8 · Cited by 77
CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE
Clegg, A. J., Bryant, J., Nicholson, T., McIntyre, L., Broe, S. D., Gerard, K., & Waugh, N. R. (2002) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646230200034x · Cited by 76
Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep
Riemann, D. W., Gann, H., Dreßing, H. R., Müller, W. E., & Aldenhoff, J. B. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90013-2 · Cited by 75
GALANTAMINE: A REVIEW OF ITS USE IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA
Corey, J. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10467.x · Cited by 72
Galasko, D., Kershaw, P. R., Schneider, L. S. S., Zhu, Y., & Tariot, P. N. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52303.x · Cited by 66
Self-citationThe effects of galantamine treatment on caregiver time in Alzheimer's disease
Sano, M., Wilcock, G. K., van Baelen, B., & Kavanagh, S. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1000 · Cited by 62
Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans
Thomsen, T., Bickel, U., Fischer, J. P., & Kewitz, H. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316106 · Cited by 62
Galantamine: a review of its use in Alzheimer's disease and vascular dementia.
Corey‐Bloom, J. (2003) · PubMed · Cited by 60
Fulton, B., & Benfield, P. (1996) · Drugs & Aging · doi:10.2165/00002512-199609010-00006 · Cited by 58
Migliaccio–Walle, K., Getsios, D., Caro, J. J., Ishak, K. J., O’Brien, J. A., & Papadopoulos, G. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80171-6 · Cited by 56
Blesa, R., Davidson, M., Kurz, A., Reichman, W. E., van Baelen, B., & Schwalen, S. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000067974 · Cited by 56
Caro, J. J., Ward, A., Ishak, K. J., Migliaccio–Walle, K., Getsios, D., Papadopoulos, G., & Torfs, K. (2002) · BMC Neurology · doi:10.1186/1471-2377-2-6 · Cited by 54
Kurz, A., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. V. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00677.x · Cited by 54
Galanthamine in Alzheimer??s Disease
Rainer, M. K. (1997) · CNS Drugs · doi:10.2165/00023210-199707020-00001 · Cited by 50
Bullock, R. A., Erkinjuntti, T., Lilienfeld, S., & Gcdp Group (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000074140 · Cited by 49
Cholinergic neurotransmission, REM sleep and depression
Riemann, D. W., Hohagen, F., Bahro, M., Lis, S., Stadmüller, G., Gann, H., & Berger, T. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90132-5 · Cited by 48
Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease
Lyketsos, C. G., Reichman, W. E., Kershaw, P. R., & Zhu, Y. (2004) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200409000-00005 · Cited by 43
Galantamine in vascular dementia and Alzheimer’s disease combined with cerebrovascular disease
KERTESZ, A. E. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0036-z · Cited by 43
Stahl, S. M., Markowitz, J. S., Papadopoulos, G., & Sadik, K. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003214 · Cited by 42
Markowitz, J. S., Gutterman, E. M., Lilienfeld, S., & Papadopoulos, G. (2003) · SLEEP · doi:10.1093/sleep/26.5.602 · Cited by 42
Clinical studies with galanthamine
Rainer, M. (1997) · Drugs of today · doi:10.1358/dot.1997.33.4.425053 · Cited by 41
Maelicke, A., Coban, T., Storch, A., Schrattenholz, A. S., Pereira, E. F. R., & Albuquerque, E. X. (1997) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899709036592 · Cited by 39
Wilkinson, D. G., Hock, C., Farlow, M. R., van Baelen, B., & Schwalen, S. (2002) · PubMed · Cited by 39
Small, G. W., Erkinjuntti, T., Kurz, A., & Lilienfeld, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317120-00004 · Cited by 37
Wilkinson, D., Hock, C., Farlow, M. R., van Baelen, B., & Schwalen, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11310.x · Cited by 29
Mintzer, J. E., & Kershaw, P. R. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.826 · Cited by 28
Pharmacokinetics and metabolism of galanthamine
Kewitz, H. (1997) · Drugs of today · doi:10.1358/dot.1997.33.4.425052 · Cited by 27
Snorrason, E., Geirsson, Á. J., & Stefánsson, K. (1996) · Journal of Chronic Fatigue Syndrome · doi:10.1300/j092v02n02_04 · Cited by 22
Patterson, C. E., Passmore, A. P., & Crawford, V. L. S. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.0107.x · Cited by 20
Galantamine alleviates caregiver burden in Alzheimer's disease: A 6-month placebo-controlled study
Wilcock, G. K., & Lilienfeld, S. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83423-5 · Cited by 14
The Clinical Efficacy and Safety of Galantamine in the Treatment of Alzheimer's Disease
Dengiz, A., & Kershaw, P. R. (2004) · CNS Spectrums · doi:10.1017/s1092852900009378 · Cited by 13
Galantamine in the Treatment of Vascular Dementia
Brashear, H. R. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009189 · Cited by 11
Use of galantamine to treat vascular dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11450-4 · Cited by 8
Erkinjuntti, T. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.04455.x · Cited by 8
Non-cognitive benefits of galantamine (Reminyl® ) treatment in vascular dementia
Kurz, A. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.106.s178.5.x · Cited by 7
Cited by
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Self-citationWaldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Self-citation
Metadata
- Authors
- Loy, C., & Schneider, L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-01-25
- Volume
- 2009
- Issue
- 1
- Pages
- CD001747-CD001747
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1930672392
- Cited by
- 322
- References
- 76
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.